218 related articles for article (PubMed ID: 37480153)
1. Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy.
Ding Z; Wang S; Shi Y; Fei X; Cheng B; Lu Y; Chen J
J Med Chem; 2023 Aug; 66(15):10364-10380. PubMed ID: 37480153
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy.
Yang Z; Liu Z; Xu C; Xu J; Liu T; He H; Li L; Ren Y; Chen J
Bioorg Chem; 2023 Oct; 139():106740. PubMed ID: 37478546
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
Cao H; Cheng B; Liu T; Chen J
Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
8. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
[TBL] [Abstract][Full Text] [Related]
9. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
11. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
13. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
14. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents.
Liu J; Cheng Y; Yuan L; Liu T; Ruan Y; Ren Y; Li L; Jiang S; Xiao Y; Chen J
J Med Chem; 2023 Sep; 66(18):13172-13188. PubMed ID: 37674362
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy.
Cheng B; Shi Y; Shao C; Wang S; Su Z; Liu J; Zhou Y; Fei X; Pan W; Chen J; Lu Y; Xiao J
J Med Chem; 2024 Apr; 67(8):6253-6267. PubMed ID: 38587857
[TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
[TBL] [Abstract][Full Text] [Related]
20. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]